GPI: An indicator for immune infiltrates and prognosis of human breast cancer from a comprehensive analysis.

Glucose-6-phosphate isomerase () plays an important part in gluconeogenesis and glycolysis through the interconversion of d-glucose-6-phosphate and d-fructose-6-phosphate, and its clinical significance still remains unclear in breast cancer (BRCA). We analyzed the expressions of in BRCA patients to determine prognostic values. Our results showed that the expression levels of were upregulated in BRCA patients, and a high expression is correlated with poor overall survival (OS) in BRCA. At the same time, a high expression is correlated with poor clinicopathological characteristics, such as stage III, over 60 years old, N3, HER2 negative, and estrogen receptor (ER) positive. Further analysis of the influence of on the prognosis of BRCA suggested that 50 genes and 10 proteins were positively correlated with , and these genes and proteins were mainly involved in cell cycle signaling pathways. In addition, in this study, we observed that was closely related to -methyladenosine (m6A) RNA methylation modification and immune cell infiltration and ferroptosis-related gene expression in BRCA, and there was a difference in m6A RNA methylation alterations, immune cell infiltration, and ferroptosis-related gene expression between the high expression group and the low expression group. Finally, we found that in BRCA had 2.6% gene alterations, and BRCA patients with gene alteration of had a poor prognosis in disease-free survival (DFS). Altogether, our work strongly suggested that may serve as a new prognostic biomarker for BRCA patients.